Introduction: Since 2008 United State (US) food drug administration mandate. several newer anti-diabetic drugs (ADD) have undergone a mandatory cardiovascular (CV) outcome trial (CVOT) in type diabetes (T2DM) patients with high CV risk. These includes CVOT done with dipeptidyl-peptidase-4 inhibitors. sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agoni... https://www.roneverhart.com/Milwaukee-2649-20-M18-Orbital-1-4-Sheet-Sander/